EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES

被引：0
|
作者：
Zhang, Q. [1 ]
Ruff, D. D. [1 ]
Pearlman, E. M. [2 ]
Govindan, S. [3 ]
Aurora, S. [4 ]
机构：
[1] Eli Lilly & Co, Stat Neurosci LTC, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Migraine Headache, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Med Writing, LCCI Biometr, Bangalore, Karnataka, India
[4] Eli Lilly & Co, Gakanezumab Launch, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-0
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [41] Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study
    Arnold, Douglas L.
    LaGanke, Christopher
    Obradovic, Dragana
    Gudesblatt, Mark
    Yang, Lili
    Miller, Catherine
    Leigh-Pemberton, Richard
    Lopez-Bresnahan, Maria
    Kandinov, Boris
    Wolinsky, Jerry S.
    NEUROLOGY, 2019, 92 (15)
  • [42] Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
    Naismith, Robert T.
    Wolinsky, Jerry S.
    Wundes, Annette
    LaGanke, Christopher
    Arnold, Douglas L.
    Obradovic, Dragana
    Freedman, Mark S.
    Gudesblatt, Mark
    Ziemssen, Tjalf
    Kandinov, Boris
    Bidollari, Ilda
    Lopez-Bresnahan, Maria
    Nangia, Narinder
    Rezendes, David
    Yang, Lili
    Chen, Hailu
    Liu, Shifang
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (13) : 1729 - 1739
  • [43] Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 study
    Bergh, F. Then
    Singer, B. A.
    Drulovic, J.
    Bidollari, I.
    Chen, H.
    Englishby, R.
    Hanna, J.
    Kandinov, B.
    Lopez-Bresnahan, M.
    Leigh-Pemberton, R.
    Miller, C.
    Mokliatchouk, O.
    Shafer, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 861 - 862
  • [44] Three-years of continuous entecavir treatment in Chinese patients who had previously failed lamivudine: Results from studies ETV-056 and -050
    Yao, Guang-Bi
    Xu, Dao-Zhen
    Ren, Hong
    Zhou, Xia-Qiu
    Jia, Ji-Dong
    Wang, Yu-Ming
    Chen, Cheng-Wei
    Liu, Jessica
    Xu, Deng
    Llamoso, Cyril
    GASTROENTEROLOGY, 2008, 134 (04) : A810 - A810
  • [45] Three-years of continuous entecavir treatment in chinese patients who had previously failed lamivudine: Results from studies ETV-056 and -050
    Yao, G. B.
    Xu, D. Z.
    Ren, H.
    Zhou, X. Q.
    Jia, J. D.
    Wang, Y. M.
    Chen, C. W.
    Liu, J.
    Xu, D.
    Llamoso, C.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S267 - S267
  • [46] Efficacy and Safety Outcomes with Diroximel Fumarate in Patients with a History of Prior Sphingosine1-Phosphate Receptor Modulators or High-Efficacy Therapies as their Most Recent Therapy: Results from the Phase 3 EVOLVE-MS-1 Study
    Singer, B. A.
    Wray, S.
    England, S. M.
    Branco, F.
    Scaramozza, M.
    Levin, S.
    Chen, H.
    Yun, I.
    Bergh, F. Then
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 53 - 54
  • [47] EFFICACY OF ERENUMAB IN PATIENTS WITH EPISODIC MIGRAINE WHO HAVE FAILED 2-4 PRIOR PREVENTIVE TREATMENTS: RESULTS FROM PRESPECIFIED SUBGROUP ANALYSES OF THE LIBERTY STUDY
    Reuter, U.
    Ferrari, M. D.
    Goadsby, P. J.
    Lanteri-Minet, M.
    Hours-Zesiger, P.
    Wen, S.
    Klatt, J.
    CEPHALALGIA, 2018, 38 : 88 - 89
  • [48] Long-termSafety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
    Contreras, Gabriel
    Baker, Matt
    Hodge, Lucy
    Yap, Ernie
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2971 - 2971
  • [49] Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM
    Vey, Norbert
    BLOOD, 2018, 132
  • [50] Interim results of a pilot study of the combination of type 1 (IFN alfacon-1) and type 2 (IFN gamma-1b) interferons in chronic hepatitis C patients who have failed to respond to Peg-interferon alpha 2 plus ribavirin
    Leevy, CB
    Ramaraju, G
    Chalmers, CP
    Blatt, LM
    GASTROENTEROLOGY, 2004, 126 (04) : A667 - A668
12345